United Therapeutics Corporation (NASDAQ:UTHR) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET

Company Participants

Dewey Steadman – Head of Investor Relations

Martine Rothblatt – Chairperson and Chief Executive Officer

Michael Benkowitz – President and Chief Operating Officer

James Edgemond – Chief Financial Officer and Treasurer

Pat Poisson – Executive Vice President of Technical Operations

Leigh Peterson – Senior Vice President of Product Development & Xenotransplantation

Conference Call Participants

Terence Flynn – Morgan Stanley

Hartaj Singh – Oppenheimer

Joseph Thome – TD Cowen

Eun Yang – Jefferies

Jessica Fye – JPMorgan

Ash Verma – UBS

Operator

Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2023 Earnings Webcast. My name is Rocco, and I will be your conference operator today. All participants on the call portion of this webcast will be in a listen-only mode until the question-and-answer portion of this earnings call. [Operator Instructions] Please note, this call is being recorded.

I will now turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics. Please go ahead.

Dewey Steadman

Thank you, Rocco, and good morning, everyone. It’s my pleasure to welcome you to the United Therapeutics third quarter 2023 earnings webcast. Accompanying me today are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; Pat Poisson, our Executive Vice President of Technical Operations; and Dr. Leigh Peterson, our Executive Vice President of Product Development & Xenotransplantation.

Remarks today will include forward-looking statements, representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q contain additional information on these risks and uncertainties, and we assume no obligation to update these forward-looking statements.

Also today’s remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making, or to suggest that any products are safe and effective during any unapproved or investigational uses.

Full prescribing information for our products are available on our website. Note that, Pat Poisson and I will be presenting in a fireside chat session in one-on-one meetings at the 2023 UBS Biopharma Conference on November 8. And Martine Rothblatt will participate in a fireside chat and one-on-one meetings at the JPMorgan Healthcare Conference in early January.